华法林与阿司匹林治疗脑梗死伴非瓣膜性心房颤动的疗效

Comparison of Efficacy of Warfarin and Aspirin in Cerebral Infarction With Nonvalvular Atrial Fibrillation

目的探讨华法林与阿司匹林在脑梗死伴非瓣膜性心房颤动患者二级预防中的有效性和安全性。方法随机选取就诊治疗的脑梗死伴非瓣膜性心房颤动患者40例作为研究对象,随机分为两组,对照组和观察组,每组各20例。其中,对照组患者使用阿司匹林,观察组患者使用华法林。结果华法林能有效预防脑梗死伴非瓣膜性房颤患者出现脑栓塞和脑出血,在严密监测并控制INR条件下调整剂量,华法林安全有效,不会增加房颤患者脑出血发生率,且不良反应较少。结论华法林在脑梗死伴非瓣膜性心房颤动患者二级预防中的有效性优于阿司匹林,二者之间安全性无明显差异。

Objective To investigate the use of warfarin and aspirin in cerebral infarction associated with efcacy and safety of secondary prevention in patients with nonvalvular atrial fbrillation. Methods 40 patients with non-valvular atrial fbrillation after cerebral infarction were randomly divided into two groups, control group and observation group, each group had 20 cases.The patients in the control group were treated with warfarin.Aspirin was used in the observation group. Results Warfarin can effectively prevent cerebral embolism and cerebral hemorrhage in patients with cerebral infarction and non valvular atrial fbrillation. Warfarin was safe and efective under the condition of strict monitoring and control of INR. Warfarin didn’t increase the incidence of cerebral hemorrhage in patients with atrial fbrillation, and had fewer adverse reactions. Conclusion Warfarin is more effective than aspirin in secondary prevention of cerebral infarction with non-valvular atrial fbrillation, and there is no signifcant diference in safety between the two.